Questioning Chemotherapy
Ralph Moss
Equinox Press, 144 St. John’s Place, Brooklyn, New York 11217. USA

This book by Ralph Moss is profoundly different from its predecessors. In my opinion, it is of great importance in the history of medicine as it describes with extreme precision the caesura in the field of medicine which has become obvious everywhere. This is clearly exemplified by the sweeping failure of the orthodox, “toximolecular” school of medicine in treating diseases.

The disaster involving toxic chemotherapy in the treatment of cancer, which has now become apparent, is the most important example of this failure of the orthodox, mechanical and unbiological school of thought in medicine. In a few years there will be a similar rude awakening in the field of chronic heart and circulatory diseases as well as decalcification diseases, resulting in far-reaching changes in these areas as well.

I have known Ralph Moss for more than 24 years from my repeated visits to the Sloan-Kettering Cancer Institute in New York, one of the leading institutes in the world. For years Ralph was the research spokesman for this Institute. His immense expertise and at the same time his detailed knowledge and integrity qualified him for this position. One of the great experienced experimental researchers in that Institute was Kanematsu Sugiura. He found that substances made of bitter almonds and apricot pits, the so-called mandelonitriles, prevented lung metastases in experiments with animals. This knowledge did not fit into the concept of oncological “orthodox medicine” in the United States or in Germany, since it sabotaged their crusade against using “Laetrile,” an 1-glucose mandelonitrile made from the pits of certain rare apricots.

When the order from higher-ups was issued to suppress the Sugiura results, Ralph Moss left the Institute and bluntly revealed these cover-up practices in cancer research in one of his books. Today, the Sloan-Kettering Institute is only a shadow of what it was 25 years ago. Biologically-oriented researchers such as President Robert Good and vice-presidents Chester Stock and Lloyd Old have left the Institute or are retired.

The whole affair started by Ralph Moss is not without some tragic irony: Today’s research, which gives absolute priority to the so-called gene-reparative, non- toxic agents for treating cancer, deals predominantly with the so-called “functional aldehydes,” of which Laetrile - damned by the orthodox school of medicine - was one of the first.

When all is said and done, Ralph Moss had already begun the persistent dismantling of unbiological orthodox inflexibility in clinical oncology over 20 years ago, without those involved having taken notice.

This book by Ralph Moss, Questioning Chemotherapy, is a masterpiece of global importance in the history of medicine. The reason for this being because it dissects the enormously complex problem areas of the treatment of cancer with toxic chemotherapy by providing a very simple, clear and indisputable panorama of facts. The results show that treatment of cancer with toxic chemotherapy makes sense in some cases, but that as a hopeful solution to the whole problem of cancer treatment, it is one of the greatest disillusions in the history of medicine.

About eight years ago, Ralph Moss and I had a short discussion about the value of the well-known chemotherapeutic drug cyclophosphamide (Cytoxan). In 1956 I had worked with this new cytostatic substance in experiments at the Druckrey Laboratory in Freiburg: It was possible to heal various tumors grafted onto test rats with this substance. However, it was also possible to damage the animals - with small doses! - to such an extent that the take of the tumor rate was greatly improved. Unfortunately, this delicate balancing act between a healing and a damaging effect continues in the clinical reality of cancer patients. This applies to all toxic or non-orthomolecular chemotherapeutic drugs.

Moss also sketches the stubborn mentality of the orthodox supporters of the exclusive use of toxic chemotherapy. In my books I have on occasion predicted that the day of reckoning for the orthodox, unbiological school of medicine and its failure would be precipitated not by scientific discussion but simply by money. The tremendous explosion of costs, which threatens to destroy health care programs worldwide, are caused mainly by the errors made by the orthodox, unbiological school of medicine, based on toximolecular (instead of orthomolecular) therapies. Ralph Moss seizes on this subject in particular. The question is not only how good therapy results against cancer can be achieved, but also how much they cost.

Toxic chemotherapy, namely, does very poorly with regard to costs, cost efficiency, long-term results and usefulness in the early stages of preventive therapy. It is not unusual to encounter enormous bills for treatment: $200,000 - $600,000 for breast cancer (Moss), $84,000 (ovary cancer, Orlando), $220,000 for breast cancer (Boston), 325,000 German marks for breast cancer (Heidelberg). “It cost us 300,000 marks to kill the patient within 10 months after first diagnosing a non- Hodgkin lymphoma” (anonymous call from a doctor at a medical university). The rate of improvement after such extreme treatment is minimal, the suffering of the patients under toxic chemotherapy often very severe. Only children and adults with relatively rare tumors profit without doubt from such aggressive therapy.

If it can be foreseen that a boat is liable to sink - as in the case of toxic chemotherapy - then some thought should be given to finding a life boat. The latter can surely be found in those therapeutic procedures which aim to repair the genetic and plasma-membrane derailments of the cancerous cell. This is also the way in which Mother Nature protects her charges from cancerous derailment. The research funds have already been provided by the Creator, all we have to do is to identify His products and multiply them. Just as was the case with penicillin.

This book by Ralph Moss is recommended reading for every doctor and in particular every oncologist, preferably before his patient has read it.

(Reprint, Townsend Letter for Doctors & Patients - February/March 1997 edition)

Back to Top

Back to Health Directory